# Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

> **NCT00367484** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 460 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Rebif® (clone 484-39)

## Key facts

- **NCT ID:** NCT00367484
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2014-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367484, "Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00367484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*